Objective motion sensor assessment highly correlated with scores of global levodopa-induced dyskinesia in Parkinson's disease

Journal of Parkinson's Disease

Volumn 3, Issue 3, 2013, Pages 399-407

  Mera, Thomas O ^a   Burack, Michelle A ^b   Giuffrida, Joseph P ^a  

^a Great Lakes NeuroTechnologies Inc   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Dyskinesia; Levodopa; Parkinson's disease; Tremor

Indexed keywords

LEVODOPA;

ABNORMAL INVOLUNTARY MOVEMENT SCALE; ADULT; AGED; ARTICLE; BIOSENSOR; CLINICAL ARTICLE; CORRELATION COEFFICIENT; DISEASE SEVERITY; DYSKINESIA; ERROR; FEMALE; HUMAN; KINEMATICS; MALE; MOTION SENSOR; PARKINSON DISEASE; PREDICTION; PRIORITY JOURNAL;

ADULT; AGED; ALGORITHMS; ANTIPARKINSON AGENTS; BIOMECHANICAL PHENOMENA; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; LEVODOPA; LINEAR MODELS; MALE; MIDDLE AGED; MOVEMENT; NEUROLOGIC EXAMINATION; PARKINSON DISEASE; TREMOR; WRIST;

EID: 84888862017     PISSN: 18777171     EISSN: 1877718X     Source Type: Journal    
DOI: 10.3233/JPD-120166     Document Type: Article

References (33)

1. Jankovic J (2005) Motor fluctuations and dyskinesias in Parkinson's disease: Clinical manifestations. Mov Disord, 20(Suppl 11), S11-S16
2. Metman LV, van den Munckhof P, Klaassen AA, Blanchet P, Mouradian MM, & Chase TN (1997) Effects of suprathreshold levodopa doses on dyskinesias in advanced Parkinson's disease. Neurology, 49, 711-713
3. Van Gerpen JA, Kumar N, Bower JH, Weigand S, & Ahlskog JE (2006) Levodopa-Associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976-1990. Arch Neurol, 63, 205-209
4. Colosimo C, & De Michele M (1999) Motor fluctuations in Parkinson's disease: Pathophysiology and treatment. Eur J Neurol, 6, 1-21
5. Grandas F, Galiano ML, & Tabernero C (1999) Risk factors for levodopa-induced dyskinesias in Parkinson's disease. J Neurol, 246, 1127-1133
6. Thanvi B, Lo N, & Robinson T (2006) Levodopa-induced dyskinesia in Parkinson's disease: Clinical features, pathogenesis, prevention and treatment. Postgrad Med J, 83, 384-388
7. Pechevis M, Clarke CE, Vieregge P, Khoshnood B, Deschaseaux-Voinet C, Berdeaux G, Ziegler M,&Trial Study G (2005) Effects of dyskinesias in Parkinson's disease on quality of life and health-related costs: A prospective European study. Eur J Neurol, 12, 956-963
8. Chapuis S, Ouchchane L, Metz O, Gerbaud L, & Durif F (2005) Impact of the motor complications of Parkinson's disease on the quality of life. Mov Disord, 20, 224-230
9. DamianoAM,McGrathMM,WillianMK,Snyder CF,LeWitt PA, Reyes PF, Richter RR, & Means ED (2000) Evaluation of a measurement strategy for Parkinson's disease: Assessing patient health-related quality of life. Qual Life Res, 9, 87-100
10. Carignan B, Daneault J, & Duval C (2011) Assessing drug-induced dyskinesia in the clinic, the laboratory and the natural environment of patients. J Parkinsons Dis, 1, 329-337
11. Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stern MB, Dodel R, Dubois B, Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, LeWitt PA, Nyenhuis D, Olanow CW, Rascol O, Schrag A, Teresi JA, van Hilten JJ, LaPelle N, & Movement Disorder Society URTF (2008) Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results. Mov Disord, 23, 2129-2170
12. Guy W. (1976) Abnormal Involuntary Movement Scale. ECDEU Assessment Manual for Psychopharmacology, 534-537
13. Goetz CG, Nutt JG,&Stebbins GT (2008) The Unified Dyskinesia Rating Scale: Presentation and clinimetric profile. Mov Disord, 23, 2398-2403
14. Widner H,&Defer GL (1999) Dyskinesias assessment: From CAPIT to CAPSIT. Core Assessment Program for Intracerebral Transplantations. Core Assessment Program for Surgical Interventional Therapies. Mov Disord, 14(Suppl 1), 60-66
15. Defer GL, Widner H, Marie RM, Remy P, & Levivier M (1999) Core assessment program for surgical interventional therapies in Parkinson's disease (CAPSIT-PD). Mov Disord, 14, 572-584
16. Stone AA, Shiffman S, Schwartz JE, Broderick JE, & Hufford MR (2003) Patient compliance with paper and electronic diaries. Control Clin Trials, 24, 182-199
17. Giuffrida JP, Riley DE, Maddux BN, & Heldman DA (2009) Clinically deployable Kinesia technology for automated tremor assessment. Mov Disord, 24, 723-730
18. Griffiths R, Kotschet K, Arfon S, & Johnson XUZ,W(2012) Automated assessment of bradykinesia and dyskinesia in Parkinson's disease. J Parkinsons Dis, 2, 47-55
19. Heldman DA, Giuffrida JP, Chen R, Payne M, Mazzella F, Duker AP, Sahay A, Kim SJ, Revilla FJ, & Espay AJ (2011) The modified bradykinesia rating scale for Parkinson's disease: Reliability and comparison with kinematic measures. Mov Disord, 26, 1859-1863
20. Hoff JI, van den Plas AA, Wagemans EA, & van Hilten JJ (2001) Accelerometric assessment of levodopa-induced dyskinesias in Parkinson's disease. Mov Disord, 16, 58-61
21. Keijsers NL, HorstinkMW,&Gielen SC (2003) Online monitoring of dyskinesia in patients with Parkinson's disease. IEEE Eng Med Biol Mag, 22, 96-103
22. Manson AJ, Brown P, O'Sullivan JD, Asselman P, Buckwell D, & Lees AJ (2000) An ambulatory dyskinesia monitor. J Neurol Neurosurg Psychiatry, 68, 196-201
23. Gibb WR, & Lees AJ (1988) The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry, 51, 745-752
24. Katzenschlager R, Schrag A, Evans A, Manson A, Carroll CB, Ottaviani D, Lees AJ, & Hobart J (2007) Quantifying the impact of dyskinesias in PD: The PDYS-26: A patient-based outcome measure. Neurology, 69, 555-563
25. Durif F, Vidailhet M, Debilly B, & Agid Y (1999)Worsening of levodopa-induced dyskinesias by motor and mental tasks. Mov Disord, 14, 242-245
26. Keijsers NL, Horstink MW, & Gielen SC (2003) Automatic assessment of levodopa-induced dyskinesias in daily life by neural networks. Mov Disord, 18, 70-80
27. Elble RJ, Pullman SL, Matsumoto JY, Raethjen J, Deuschl G, Tintner R, & Tremor Research G (2006) Tremor amplitude is logarithmically related to 4-And 5-point tremor rating scales. Brain, 129, 2660-2666
28. Mera TO, Filipkowski DE, Riley DE, Whitney CM, Walter BL, Gunzler SA, & Giuffrida JP (2013) Quantitative analysis of gait and balance response to deep brain stimulation in Parkinson's disease. Gait Posture, 38, 109-114
29. Pahwa R, Factor SA, Lyons KE, Ondo WG, Gronseth G, Bronte-Stewart H, Hallett M, Miyasaki J, Stevens J, Weiner WJ, & Quality Standards Subcommittee of the American Academy of N (2006) Practice Parameter: Treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology, 66, 983-995
30. Mera TO, Heldman DA, Espay AJ, Payne M, & Giuffrida JP (2012) Feasibility of home-based automated Parkinson's disease motor assessment. J Neurosci Methods, 203, 152-156
31. Keijsers NL, Horstink MW, & Gielen SC (2003) Movement parameters that distinguish between voluntary movements and levodopa-induced dyskinesia in Parkinson's disease.Hum Mov Sci, 22, 67-89
32. Fenney A, Jog MS, & Duval C (2008) Short-Term variability in amplitude and motor topography of whole-body involuntary movements in Parkinson's disease dyskinesias and in Huntington's chorea. Clin Neurol Neurosurg, 110, 160-167
33. Heldman DA, Filipkowski DE, Riley DE, Whitney CM, Walter BL, Gunzler SA, Giuffrida JP, & Mera TO (2012) Automated motion sensor quantification of gait and lower extremity bradykinesia. Conf Proc IEEE Eng Med Biol Soc, 2012, 1956-1959